메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

SUZHOU, China, Dec. 4, 2025 -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical data (as of September 19, 2025) for its lead HSV-1 oncolytic virus product. MVR-T3011, in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The patients were enrolled and treated with intravesical MVR-T3011 at two dose levels: 2x109 PFU and 1x1010 P
- 김갑성 기자
- 2025-12-04 08:00
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting

[ 메디채널 김갑성 기자 ] Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. PALO ALTO, Calif., Dec. 4, 2025 -- ImpriMed, a precision oncology CRO specializing in ex vivo drug sensitivity testing for hematologic malignancies, announced today that it has been selected to present two significant research studies at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, taking place December 6-10. "Being featured at ASH is an important validation of our xC
- 김갑성 기자
- 2025-12-04 01:00
Emerald Clinical Appoints Luke Gill as Vice President, Global Head of Oncology, Medical & Scientific Affairs

Accomplished biotech and CRO leader brings 25+ years of global oncology drug development and operational excellence to propel Emerald's continued growth. SINGAPORE, Dec. 3, 2025 -- Emerald Clinical Trials, a leading global clinical research organization (CRO), today announced the appointment of Luke Gill, MSc, MBA, as Vice President, Global Head of Oncology, Medical & Scientific Affairs. This appointment underscores Emerald's continued investment in advancing oncology innovation and delivering high-performing, science-driven clinical programs worldwide. Luke brings m
- 김갑성 기자
- 2025-12-03 21:10
U.S. POINTER의 구조화된 건강 생활습관 프로그램, 인지기능 개선 입증 이어 수면 무호흡 및 혈압 조절, 인지 회복력 향상 효과 확인

- NIH(미국 국립보건원) 지원 3개 부속 연구에서 2년 생활습관 중재 "레시피" 테스트 진행 - 주요 시사점 NIA(미국 국립노화연구소)가 지원한 U.S. POINTER 임상시험의 3개 부속 연구 결과, 뇌 영상, 수면 건강, 혈압 조절 측면에서 유익한 효과가 확인되었다. U.S. POINTER 레시피는 정기적이고 구조화된 지원을 포함하는 2년 기간의 다영역 건강 생활습관 중재로, 뇌 혈류의 혈압 조절 기능을 개선하고 수면 무호흡 건수를 감소시켰으며, 특정 알츠하이머 관련 뇌 변화가 있는 성인의 인지 회복력을 높였다. 샌디에고, 2025년 12월 3일 -- 인지 저하 위험이 있는 성인 인지기능을 개선할 수 있다고 밝혀진 정기적이고 구조화된 지원을 포함한 2년 기간의 다영역 건강 생활습관 중재가 혈압 조절 기능을 개선하고 시간당 수면 무호흡 호흡 사건을 줄일 수 있다는 새로운 연구 결과가 오늘 샌디에이고에서 열린 2025년 알츠하이머병 임상시험 학회(CTAD 2025)에서 발표되었다. 또한 이 중재는 특정 알츠하이머병 관련 뇌 변화로 인한 부정적인 인지 영향으로부터 뇌를
- 김갑성 기자
- 2025-12-03 20:43
Waterdrop Inc. Announces Third Quarter 2025 Unaudited Financial Results, Net profit rises 60.1% year-on-year

BEIJING, Dec. 3, 2025 -- On December 3, 2025, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the three months ended September 30,2025. During the quarter, Waterdrop reported net operating revenue of RMB 974.9 million, representing an increase of 38.4% year-over-year. Net profit attributable to ordinary shareholders totaled RMB 158.5 million, up 60.1% from the previous year, sustaining profitability for the fifteenth consecutive quarter. Operating expenses, inc
- 김갑성 기자
- 2025-12-03 19:45
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (R/RDLBCL) and as a combination therapy when used together with bortezomib and dexamethasone (XVd) for MM patients who received at least one prior therapy. - XPOVIO® is the first approved XPO1 inhibitor in Hong Kong. With expanding indications in MM and DLBCL, XPOVIO® i
- 김갑성 기자
- 2025-12-03 17:00
S3 Connected Health Receives Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity

[ 메디채널 김갑성 기자 ] Recognized for pioneering advancements that redefine medical device connectivity, accelerate home-based care, and deliver transformative value across global healthcare ecosystems. SAN ANTONIO, Dec. 3, 2025 -- Frost & Sullivan is pleased to announce that S3 Connected Health has received the 2025 Global Company of the Year Recognition in the Medical Device Connectivity (MDC) industry for its outstanding achievements in driving technology innovation, advancing care delivery, and enabling seamless connectivity from hospital to home. This recognition highlights the com
- 김갑성 기자
- 2025-12-03 16:00
뉴소프트 메디컬 시스템즈, 2025 북미영상의학회에서 세계 최초 8cm 광역 커버리지 광자 계수 CT 및 프리미엄 혁신 기술 공개

[ 메디채널 김갑성 기자 ] 시카고 2025년 12월 3일 -- 글로벌 의료 영상 선도 기업인 뉴소프트 메디컬 시스템즈(Neusoft Medical Systems Co., Ltd., 이하 '뉴소프트 메디컬')가 2025 북미영상의학회(Radiological Society of North America, RSNA) 연례 회의에서 포괄적인 지능형 헬스케어 혁신 포트폴리오를 선보인다. 이번 전시의 하이라이트는 세계 최초의 8cm 광역 커버리지 광자 계수(photon-counting) CT인 NeuViz P10의 획기적인 출시다. 이와 함께 다양한 하이엔드 영상 시스템 및 인공지능(AI) 통합 임상 솔루션도 함께 전시된다. 현장 시연에서는 검진, 진단, 치료, 재활 및 연구를 아우르는 전주기 지능형 영상 생태계를 제시하며, 임상 결과 개선을 위한 효율적이고 연결된 경로를 제공한다. 뉴소프트 메디컬 부사장인 장단(Zhang Dan) 국제 비즈니스 센터 총괄은 "이 글로벌 무대에서 탁월한 영상 성능과 지능형 케어를 제공하는 첨단 기술을 선보이게 되어 영광"이라면서 "혁신적인 광자 계수 CT인 Neu
- 김갑성 기자
- 2025-12-03 14:59
Waterdrop Wins 2025 Global Best Case Brands Award, Empowering Inclusive Protection Through Technological Innovation

BEIJING, Dec. 3, 2025 -- Waterdrop Inc. (NYSE: WDH) was honored with the Global Best Case Brands Award at the 3rd International Conference on Management Change and Sustainable Development (MC&SD). Selected from more than 100 nominated companies, Waterdrop stood out for its significant contributions and innovative practices in advancing inclusive protection. The conference was hosted by Jiangxi University of Finance and Economics (JUFE) and organized by its School of Business Administration. Nearly 300 industry experts, researchers, and business leaders from North America, E
- 황정호 기자
- 2025-12-03 11:32
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery

SINGAPORE, Dec. 3, 2025 -- MediThinQ, a fast-growing innovator in surgical displays and digital 3D microscopy, today announced that world-renowned reconstructive microsurgeon Prof. Joon-pio Hong has joined the company as Chief Medical Officer. His decision marks one of the strongest clinical endorsements to date for MediThinQ's next-generation digital microsurgery platform, SHIYA 20. Prof. Hong is President of the World Society for Reconstructive Microsurgery, Professor at Asan Medical Center in Korea, and Adjunct Professor at Georgetown University in the United States. Widely
- 김갑성 기자
- 2025-12-03 09:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-12-19_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 19일 15시 20분